Jennifer J. Rhodes - Mar 24, 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, CHIEF LEGAL OFFICER, SEC
Signature
/s/ Jennifer J. Rhodes
Stock symbol
ACAD
Transactions as of
Mar 24, 2025
Transactions value $
$0
Form type
4
Date filed
3/26/2025, 08:03 PM
Previous filing
Feb 8, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACAD Common Stock 1.02K Mar 24, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +102K $0.00 102K Mar 24, 2025 Common Stock 102K $17.23 Direct F2
transaction ACAD Restricted Stock Units Award $0 +30.1K $0.00 30.1K Mar 24, 2025 Common Stock 30.1K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on November 15, 2024.
F2 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F3 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F4 The restricted stock units vest in four equal annual installments beginning March 24, 2026.